Plain-English translation of NCT04093167 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a simple blood test can help doctors choose the best treatment plan for people with advanced lung cancer. You would receive , an immunotherapy medication that helps your immune system fight cancer, and doctors would use blood tests to check if the medication is working. If blood tests show the cancer is still present after 6 weeks, you might then receive additional chemotherapy to improve your results.
Some patients respond very well to immunotherapy alone, while others benefit from adding chemotherapy. This trial exists to figure out which patients need the extra chemotherapy by using blood tests to detect cancer cells early, before the cancer gets worse on imaging scans.
You would start receiving as your first treatment for advanced lung cancer. After 6 weeks, you would have a blood test to see if cancer cells are still detectable. If they are, you would be randomly assigned to either continue alone or add standard chemotherapy to your treatment. You would have regular clinic visits, blood tests, and imaging scans to monitor how the treatment is working throughout the study.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Canada